Virgin Voyages Sets Sights on the Med for Second Ship ‘Valiant Lady’ Launching 3 Exhilarating 7-night Itineraries From Barcelona With Overnights in Ibiza
19.11.2019 17:02:00 EET | Business Wire | Press release
Virgin Voyages, the new lifestyle brand shaking up the travel industry, announced their second ship will be called ‘Valiant Lady’ and that she will sail 7-night Mediterranean itineraries out of Barcelona, Spain when she debuts in May 2021. Bookings for the three feature itineraries, that all offer overnight and late-night stops across some of the hottest destinations in France, Italy and Spain, will open December 19, 2019.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005362/en/
Virgin Voyages Sets Sights on the Med for Second Ship ‘Valiant Lady’ (Graphic: Business Wire)
“We are thrilled to unveil the name of our second ship - Valiant Lady - and to deliver on our commitment to offer travelers a sea change in how they can experience cruising in this fantastic part of the world. Our Sailors will fall in love with the places we go and the moments and memories they will be able to create on our gorgeous ship. After all, there is no better way to sail the seven seas than doing it the Virgin way,” said Tom McAlpin, CEO of Virgin Voyages.
2021 Summers on the Med with a home in Barcelona
Valiant Lady will dock just steps from Las Ramblas at the World Trade Center Barcelona, positioning Sailors as close to the heart of this stunning departure-port-city as possible. This prime location, usually reserved by luxury liners and mega-yachts, gives walking access to the dynamic and diverse neighborhoods of Poble Sec, el Raval, Barri Gotic, Port Vell and the famed urban beach of La Barceloneta. With a weekly Sunday sail away, Sailors will enjoy extra time in Barcelona and be able to take advantage of many different flight options. Virgin Voyages is partnering with Global Ports Holding, the world’s leading independent cruise port operator, to prepare for Valiant Lady’s arrival in early summer 2021.
Open for bookings December 2019, 7 night sailings start May 2021 and feature an overnight in Ibiza
The Med, home to some of the world’s best beach clubs, cultural experiences, restorative spas, yacht clubs and nightlife, is a perfect choice for Virgin Voyages. Valiant Lady will sail 3 different itineraries with truly breathtaking ports of call.
- Itinerary 1 includes the exotic delights of Barcelona, Ibiza, Monte Carlo, Marseille and Olbia
- Itinerary 2 includes a fantastic sampling of the Med featuring Barcelona, Ibiza, Toulon, Ajaccio, Marina di Carrara and Cagliari
- Itinerary 3 is a mostly Spanish immersion, stopping by Barcelona, Ibiza, Palma de Mallorca, Malaga and the British port of Gibraltar
Hearing Sailor and First Mates (travel partners) requests for later stays in ports, Virgin has delivered this on every itinerary. This means Sailors have the flexibility to make the most of their time in port and take in all that these destinations have to offer. Of particular note, every sailing features a Friday overnight stay in Ibiza, one of the most stunning and thrilling Balearic Islands. Whether it’s a blissed out beach club, a bohemian market, a serene spa, watching the stunning sunsets, or a late night out, there is no comparable place that offers the variety and style of this ultimate destination.
Introducing ‘Valiant Lady’
Virgin Voyages also revealed that the name ‘Valiant Lady’ was inspired by the Latin word valere and from the French origin, vaillant, meaning “bold”, “strong”, and “courageous." While historically, the image of women only graced the bows of ships to bring protection to a vessel, ‘Valiant Lady’ embodies the idea that women design, captain, lead and champion change in the maritime industry.
The Scarlet Lady’s sister ship ‘Valiant Lady’ will continue Virgin Voyages’ ‘Scarlet Squad’ program aimed at recruiting, supporting and mentoring female shipboard talent, and growing opportunities to access leadership roles in onboard areas such as marine, technical and hotel management that statistically show low numbers of female leadership.
All Virgin Voyages ships have been designed by a leading creative collective who are the brains behind some of the world’s most loved boutique hotel brands. The collective includes names like Design Research Studio (Tom Dixon), Roman & Williams and Concrete Amsterdam who have all been inspired by the brand’s design concept- the Modern Romance of Sailing and Mission to Redefine the Experience of a Vacation at Sea.
Future Sailors, First Mates and travel advisors are invited to check out Virgin Voyages by visiting www.virginvoyages.com or following @virginvoyages on Instagram, Facebook, Twitter or LinkedIn.
ABOUT VIRGIN VOYAGES
Virgin Voyages is a global lifestyle brand committed to creating the world’s most irresistible holidays. The brand currently has four ships on order with master shipbuilder Fincantieri and has operations in the US, UK and Europe. Virgin Voyages’ ships are designed to reflect a super yacht’s sleek luxury, featuring spaces designed by some of the top names in contemporary interiors. An Adult-by-Design sanctuary, the ships offer a dose of Vitamin Sea with well-being activated through a mix of high-energy moments coupled with relaxation and rejuvenation. Scarlet Lady will also feature never before seen entertainment and 20+ world-class intimate eateries on board. Virgin Voyages offers incredible value for its sailors with all restaurants, group fitness classes, soft drinks, and many more Virgin surprises included within the voyage fare. Scarlet Lady will sail from Miami to the Caribbean all year round from March 2020 and Valiant Lady will sail the Mediterranean from May 2021. The fleet's ships host more than 2,770 sailors and 1,160 amazing crew from around the world. Keep watch on virginvoyages.com for more updates.
FOLLOW VIRGIN VOYAGES:
Instagram: @virginvoyages
Facebook: @virginvoyages
Twitter: @virginvoyages
LinkedIn: Virgin Voyages
YouTube: Virgin Voyages
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005362/en/
Contact information
ALISON BROD MARKETING + COMMUNICATIONS
Virgin@alisonbrodmc.com
Virgin Voyages
Michelle Estevam, media@virginvoyages.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom